Hyperprolactinemia is a frequent cause for medical referrals to endocrinology departments. Markedly elevated prolactin levels are generally indicative of macroprolactinomas, whereas mild to moderate hyperprolactinemia may arise from physiological factors (such as exercise, sleep or stress), pharmacological agents, metabolic disturbances, ...

Type 2 diabetes (T2D) is a progressive metabolic condition associated with obesity, cardiovascular disease and substantial morbidity and mortality.1 Despite the availability of multiple glucose-lowering therapies, a significant proportion of individuals with T2D fail to achieve recommended glycemic targets, ...

New data presented at ENDO 2026 highlighted the continued evolution of endocrine care, with studies spanning rare disease management, long-term hormone replacement, artificial intelligence-supported screening and real-world treatment outcomes. Across several presentations, investigators reported sustained improvements in biochemical, metabolic, skeletal and patient-reported outcomes, while also emphasising the importance of long-term follow-up and careful interpretation of emerging data.

Data presented at ENDO 2026 highlighted investigational approaches for difficult-to-control type 2 diabetes and acquired hypothalamic obesity, real-world outcomes with tirzepatide, and wider health impacts of GLP-1-based therapy.

Peripheral neuropathy is a common and clinically heterogeneous condition resulting from damage to the peripheral nervous system, affecting sensory, motor and autonomic fibers.1 Its diagnostic complexity stems from a broad spectrum of etiologies, including metabolic, autoimmune, infectious, toxic, neoplastic and ...

Adults with prediabetes who received an intensive lifestyle intervention in the Diabetes Prevention Program were less likely to develop multiple chronic conditions over long-term follow-up than those assigned to placebo, according to an analysis published in JAMA.1 A similar reduction was not observed with metformin.

New interim data from OUTSTEP 1 reveal high levels of patient satisfaction with injectable semaglutide and underscore the importance of understanding patient experiences beyond clinical trials. “While still endorsing the ‘my responsibility only’ narrative, we are learning that a new attitude ...

At EASL 2026, Manal Abdelmalek discusses a post hoc ESSENCE trial analysis showing semaglutide provides consistent liver health benefits in MASH, regardless of menopausal status, age or sex.

Pathophysiology of X-linked hypophosphataemia X-linked hypophosphataemia (XLH) is a progressive skeletal disorder, originally defined by Albright in 1937 as hypophosphataemic vitamin D rickets.1 XLH is the commonest form of inherited rickets/osteomalacia and is an X-linked dominant condition.2 The most common ...